AID Genomics

Early Detection and Personalized Treatment of Cancer and Infectious Diseases

Health Tech & Life Sciences
Private

Company Overview

Snapshot

Founded in July 2018, AID Genomics operates with 51–200 employees. In May 2026, the company participated in a female entrepreneurship event, where its CEO discussed the company's commitment to enabling Israeli citizens to participate in the 2026 elections.

Business overview

AID Genomics is a diagnostic company focused on developing precision medicine-based diagnostic solutions for oncology, hereditary rare diseases, and infectious diseases. The company leverages cutting-edge technologies, including next-generation sequencing, miRNA, epigenetics, and AI-based analytical tools, to provide accurate diagnostics and data for physicians to make informed therapy recommendations. Operating within the Health Tech & Life Sciences sector, AID Genomics aims to deliver affordable precision medicine to improve patient care and quality of life.

Strategic signal

In July 2022, AID Genomics announced the closure of its research and development operations and the layoff of 400 employees in Israel. This significant restructuring indicates a strategic shift within the company, potentially re-evaluating its operational footprint and R&D focus, which could impact its long-term product development and market strategy.

Company Intelligence Q&A

What is AID Genomics' primary focus?
AID Genomics is a diagnostic company specializing in precision medicine-based diagnostic solutions for oncology, hereditary rare diseases, and infectious diseases.
What technologies does AID Genomics utilize in its diagnostic solutions?
AID Genomics combines advanced technologies such as next-generation sequencing, miRNA, epigenetics, and AI-based analytical tools in its research and development.
What was a significant operational change for AID Genomics in July 2022?
In July 2022, AID Genomics closed its research and development operations and laid off 400 employees in Israel.
What was AID Genomics' involvement in COVID-19 testing in April 2020?
In April 2020, AID Genomics partnered with China's BGI to open a COVID-19 testing laboratory in Gaza.
What was a key announcement made by AID Genomics' CEO in May 2026?
In May 2026, AID Genomics' CEO, Batell V. Blaish-Sultanik, stated at a female entrepreneurship event that the company aims to ensure every Israeli with voting rights can be in Israel for the 2026 elections.

External links